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Abstract
Background: Recent studies have shown that disruption of circadian rhythms is one of the tumor promoting
factors which contribute to mammalian cancer development and progression, but very little is known about the
molecular changes of circadian genes in colorectal carcinoma (CRC). Thus, in this study, changes in the expression
of human Period2 (hPer2), one of the key circadian clock regulators, in CRC and its correlation with prognosis were
investigated.
Methods: Immunohistochemical (IHC) staining and real-time PCR for hPer2 were performed for 38 CRC cases.
Results: IHC analysis detected positive staining for hPer2 in 81.6% (31/38) of CRC tissues and 97.4% (37/38) of
surrounding non-cancerous tissues (P < 0.05). Most colorectal cells in non-cancerous tissues were homogeneously
stained. In contrast, in the paired cancerous tissues, a heterogeneous pattern was found with a significant portion
of cancer cells displaying negative or weak hPer2 staining. In over 60% cases (24/38), the staining for hPer2 was
much stronger in non-cancerous cells than in the paired cancerous cells. Well-differentiated cancer cells are more
likely to maintain hPer2 expression than poorly-differentiated ones. Furthermore, associations of decreased hPer2
levels with patients’ age, histological grade, TNM stage and expression of nucleus proliferation related antigen: Ki67
were also detected (P < 0.05). Expression of hPer2 did not correlate with that of either p53 or C-erB-2. Similar to
hPer2 protein expression, quantitative RT-PCR for hPer2 also showed decreased mRNA expression in CRC.
Conclusion: These results suggest a role for hPer2 in normal colorectal cell function and the potential
deregulation of hPer2 expression in the development, invasion, and metastasis of CRC.
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Background
Various kinds of living organisms exhibit behavioral and
physiological circadian rhythms, allowing them to adapt
to the daily cycle of light and dark [1]. At the molecular
level, the rhythms of the circadian clock are controlled
by the interaction between positive and negative feed-
back loops consisting of several key clock regulators
[2,3]. A model encompassing a feedback system invol-
ving heterodimer transcriptional factors (Clock and
Bmal1), two cryptochromes (Cry1 and Cry2), and three
Period (Per1, Per2, and Per3) regulators has been widely
described.
Among all the known clock genes, Per2 has been
s h o w nt op l a ya ni m p o r t a n tr o l ei nt u m o rp r o g r e s s i o n
[4,5]. Dysregulation of hPer2 gene has been found in
many types of human cancers [6,7]. Genetic studies also
showed that mice with dysfunctional circadian rhythms
are prone to many kinds of cancer developing [8,9].
Mice deficient in mPer2 showed significant higher
tumor incidence [10]. Moreover, functional studies
found that overexpression of Per2 inhibited cancer cell
growth in both culture system and xenograft mouse
model [11-13]. In terms of the mechanisms, C-erB-2
and p53 were suggested to act as the downstream
players for hPer2 in the course of tumor progression
[7,10,14]. Both the C-erbB-2 oncogene and the p53
tumor-suppressor gene integrate numerous signals that
control cell proliferation and survival. As when a highly
connected node in the internet breaks down, the
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severe consequence of tumorigenesis [15-17]. Although
hPer2 is implicated as a tumor suppressor, the expres-
sion pattern of hPer2 in cancer is not quite clear.
Whether hPer2 expression is associated with other
tumor-associate proteins such as C-erB-2 and p53 in
human CRC remains uncertain.
Colorectal cancer is one of the most commonly seen
malignancies and the leading cause of cancer related
death worldwide. About 141,210 new cases and 49,380
deaths were expected for 2011 in the United States [18].
In China, CRC is the fourth leading cause of cancer
mortality in big cities and the fifth in countryside. How-
ever, in Shanghai, CRC incidence and mortality rates
ranked the second and third respectively for female [19].
Since surgical approaches and conventional therapeutic
have not been able to fully control the outcomes of
CRC, there is an urgent need to develop more effective
treatments.
The circadian rhythm is interconnected with many
aspects of cellular functions such as cell proliferation,
migration and differentiation, thus, it plays a major role
in regulating the digestive system [20,21]. Many labora-
tories have reported strong evidence about the beneficial
effects of chronotherapy, which refer to chemotherapy
delivery according to the circadian rhythm [22,23].
Phase I-III clinical trials have shown that chronotherapy
significantly increased tolerance to high doses of che-
motherapy drugs and improved clinical response in
patients with metastatic colorectal cancer [24,25]. These
findings further interest us to explore the relationship
between circadian rhythms and CRC at molecular level.
In the present study, we used immunohistochemical
staining and real-time PCR to characterize the role of
hPer2 in the development of human CRC.
Methods
Tissue samples
38 resected CRC samples and paired non-cancerous tis-
sues were obtained from the patients of Huashan hospi-
tal, Shanghai, China, undergone radical surgery for
colorectal cancer (20 males and 18 females). All patients
had a definitive pathological diagnosis and accepted
neither chemotherapy nor radiotherapy before opera-
tion. The samples were surgically obtained at the follow-
ing points: 23 cases between 10:00 and 12:00, 8 cases
between 12:00 and 14:00, 3 cases between 14:00 and
16:00, 3 cases between 16:00 and 18:00, and 1 case at
22:00. After surgical removal, the samples were pre-
served in liquid nitrogen immediately and then moved
to the - 80°C freezer for long term storage. The age of
the patients, tumor site, tumor type, histological grade
and TNM stage according to AJCC classification were
recorded.
Immunohistochemistry
Frozen tissues were cut into 4 μm- thick sections and
adhered to slides at - 20°C, fixed by acetone and stored
in the - 20°C refrigerator. Endogenous peroxidase activ-
i t yw a sb l o c k e db yi n c u b a t i o no fs e c t i o n si n3 %H 2O2/
methanol. Sections were covered with pre-block solution
at 37°C for 30 minutes, followed by Per2 antibody (1:50,
Santa Cruz biotechnology) incubation for 60 minutes at
37°C. After a brief wash with PBS, biotinylated second-
ary antibody was added with 60 minutes at 37°C. After
several washes with PBS, staining was achieved using 3,
3’-diaminobenzidine for about 5~10 minutes. Finally,
slides were counterstained with Mayer’s hemalum and
mounted. Appropriate positive and negative controls
were also included. The frozen sections were also
stained with C-erB-2(sp3, dako), p53 (DO-7, dako) and
Ki67 (Ki-S5, dako) by the same method.
Grading of immunohistochemical findings
Immunohistochemical findings were scored depending
on the extent and intensity of staining. All sections were
graded by two independent investigators without know-
ing the patient’s outcome. At least 10 randomly selected
high - power fields were scored, and the average score
was recorded.
RNA extraction and first-strand cDNA synthesis
Preparation of total RNA from tissue samples was done
using the Trizol reagent (Invitrogen Co.). The amount
of total RNA was determined by UV spectrophotometry,
and RNA integrity was assessed by agarose gel electro-
phoresis. First-strand cDNA was prepared with oligo-dT
primers using a commercial cDNA synthesis kit (Fer-
mentas RevertAId™). The cDNA was then amplified for
33 cycles with specific primers for Per2 and GAPDH
which was utilized as an internal reference (table 1).
Sequence data were analyzed using the Basic Local
Alignment Search Tool (BLAST) software located at the
National Centre for Biotechnology Information (NCBI)
web site: http://www.ncbi.nlm.nih.gov web site.
The PCR reactions containing SYBR-green were
amplified on a Corbett Real Time PCR machine (Bio-
Rad, USA). After reverse transcription, the cDNA was
diluted with sterile deionized water to 10-fold. The reac-
tion mixtures for PCR contained 5 mL of diluted cDNA,
1 mL of 10 mmol/L primers (0.5 mL of forward primers,
Table 1 Primer pairs used for real-time PCR
primer (5’-3’) Product length
hPer2 Forward:TCCAGTGGACATGAGACCAA
Reverse:CGCTACTGCAGCCACTTGTA
186 bp
GAPDH Forward:AACCTGCCAAATATGATGAC
Reverse:ATACCAGGAAATGAGCTTGA
191 bp
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Master Mix (TOYOBO Co.), and 6.5 mL of H2O, into a
final volume of 25 mL. After an initial incubation for 5
min at 94°C, the samples were subjected to 33 cycles of
amplification (denaturation at 94°C for 30 sec, primer
annealing at 52°C for 45 sec, extension at 72°C for 45
sec) with the final incubation for 15 min at 72°C.
After each real-time PCR, melting profiles as well as
agarose gel electrophoresis of each sample were done to
rule out the possibilities of nonspecific PCR products
and primer dimers. Each 4 μL of PCR product was elec-
trophoresed on 2% agarose gel and visualized with UV
transilluminator. Data was acquired as threshold cycle
(ΔCt) value. As internal standard to normalize mRNA
levels for differences in sample concentration and load-
ing, amplification of GAPDH was used. Standard curves
were constructed for each target gene and internal con-
trol by plotting ΔCt values versus log cDNA dilution.
Because the amplification efficiencies of target genes
and internal control were equal, the relative changes of
target gene expression in tumor cells compared with
normal colorectal mucosa (ΔCt calibrator value) were
calculated using the equation 2
-ΔΔCt, where ΔΔCt = ΔCt
(cancer)-Δ(non-cancer). The ΔCt values were deter-
mined by subtracting the average GAPDH Ct value
from the average target gene Ct value.
Statistical analysis
Comparison between the expression of hPer2 mRNA
levels in normal colorectal mucosa and tumor tissue of
patients was done by paired t-test, Ki67 level with hPer2
p r o t e i ne x p r e s s i o nw a sd o n eb yt - t e s t ,a n dc
2-test or
Fisher exact test was performed to analyze the correla-
tions of hPer2 protein levels with clinical and pathologic
parameters. SPSS, 16.0 was used in the above data ana-
lysis. P-values of less than 0.05 were considered to be
statistically significant.
Results
Immunohistochemical analyses of hPer2 protein
expression
To investigate whether hPer2 gene was deregulated in
colorectal cancer, we first examined hPer2 protein
expression in 38 paired colorectal cancerous and non-
cancerous tissues by IHC staining. hPer2 expression was
found in both cytoplasm, and nucleus. The results
revealed that positively stained cells can be found in
81.6% (31/38) of colorectal carcinoma tissues (Figure
1A) and 97.4% (37/38) of surrounding non-cancerous
tissues (Figure 1B) (P < 0.05). Most colorectal cells in
non-cancerous tissues were homogeneously stained. In
contrast, in the paired cancerous tissues, there was a sig-
nificant portion of cancer cells displaying negative or
weak staining. This heterogeneous staining phenomenon
was frequently observed in our study. Moreover, well-
differentiated cancer cells tend to have comparable
hPer2 level with that in non-cancerous cells (Figure 2),
suggesting that loss of hPer2 expression may associate
with increased aggressiveness. For these 38 cases, the
hPer2 protein expression in colorectal tissues exhibited
three different patterns: typeI (24 cases): the staining for
hPer2 was much stronger in non-cancerous cells than in
the paired cancerous cells; type II (12 cases): there were
no significant differences between the staining of can-
cerous and non-cancerous cells; type III (2 cases): the
staining for hPer2 was stronger in cancerous cells than
in the paired non-cancerous cells.
Correlation between hPer2 protein expression and
clinical-pathological features in colorectal cancer patients
In order to establish the clinical and pathological rele-
vance of low expression of hPer2 protein in human col-
orectal cancer, we assessed the relationship between
hPer2 expression and clinical-pathological parameters.
The results are shown in table 2 table 3 and table 4.
Decreased hPer2 expression were found in all the
younger patients with age no more than 50 while only
53% patients in the older group had low hPer2 expres-
sion. However, no correlations were found between low
hPer2 expression and sex or tumor site.
Low hPer2 expression is also found to be correlated
with higher histological grade (p < 0.017), deeper tumor
invasion (P < 0.044), positive lymph nodes metastasis (P
< 0.043) as well as more advanced TNM stage (P <
0.021). In order to further understand the potential role
of hPer2 at molecular level, Ki67, a proliferation marker,
was also evaluated. And we found that tumors with low
hPer2 expression displayed higher Ki67 score than that
without, consistent with the notion that losing hPer2
expression may promote cancer cell growth. However,
there were no statistical differences between hPer2
expressions with expressions of p53 or C-erB-2.
Determination of hPer2 mRNA level by real-time PCR
We further analyzed hPer2 mRNA levels in these 38
paired cancerous and non-cancerous tissues by real-time
PCR. The amount of hPer2 mRNA was normalized
using the endogenous reference GAPDH. The normal-
ized hPer2 mRNA expression (ΔCt) of tumor tissue was
then compared with the ΔCt of the paired non-tumor
tissues from the same colorectal cancer patient to deter-
mine their relative expression levels (ΔΔCt) (Figure 3).
Then we analyzed hPer2 mRNA expressions in these 24
paired tissues which showed low expression of hPer2
protein in tumor. Our results showed that the mRNA
levels of hPer2 in colorectal cancer were decreased com-
pared with those in paired non-tumor tissues (P < 0.05).
The relative expression levels (2
-ΔΔCt)o fh P e r 2i n
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nents were 1: 1.219.
Discussion
Studies in breast cancer and hepatic carcinoma have
suggested that disturbed hPer2 gene expression is asso-
ciated with human tumor progression [26,27]. Genetic
studies then have provided direct evidence to show that
mPer2 is a tumor suppressor in mice [10,28]. Whether
this clock gene Per2 serves a similar role in human CRC
is unclear. Aiming to investigate this question directly,
in this study we first examined the protein expression of
hPer2 in colorectal cancer patients. In order to make
the cancerous and non-cancerous tissues be synchro-
nized to the same circadian clock and be comparable,
we analyzed and compared the expression status of the
hPer2 proteins between cancerous and non-cancerous
cells of the same patient sample. The results revealed
that hPer2 protein expressed in both colorectal carci-
noma tissues (31 cases of the total 38 cases) and sur-
rounding non-cancerous tissues (37 cases of the total 38
cases). By further comparisons of the average level of
hPer2 protein expression in the paired tissues, signifi-
cantly decreased hPer2 expression in these cancerous
tissues were found (24 cases of the total 38 cases). In
mammals, the rhythmic expression of Period genes is
essential for creating a beating clock [2,29]. Homologues
of most of the genes involved in the fly circadian clock
have been cloned in mammals, and the general core
clock mechanism of interacting transcriptional feedback
loops is similar between flies and mice [30]. Abundant
evidences generated from mammalian circadian rhythms
Figure 1 1A Immunohistochemical analyses of hPer2 protein positively expression in the colorectal cancerous tissues(200×/400×).1 B
Immunohistochemical analyses of hPer2 protein positively expression in the paired non-cancerous colorectal tissues(100×/200×).
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immediate behavioral arrhythmicity of mPer2 knock-out
mouse [31-33]. Since the Per2 gene expression level
decreased in the CRC tissues, our results may suggest
that the circadian clock in most human CRC cases
behaves arrhythmic, and differently from that in non-
cancerous cells.
Immunohistochemical analyses also showed differen-
tial expression patterns of hPer2 protein in our samples.
Most colorectal cells in non-cancerous tissues were
Figure 2 Immunohistochemical analyses of hPer2 protein heterogeneous expression in the colorectal cancerous tissues, positively
stained in well-differentiated cells. 2A and 2B are two different individuals in which this interesting phenomenon can be found(200×/400×).
Table 2 Relationship between expression levels of hPer2 protein in colorectal carcinoma and clinical features
clinical-pathological features Total cases
n
Decreased hPer2 expression in tumor
n(%)
P
Sex 0.357
male
female
18
20
10(55.6)
14(70. 0)
Age 0.017
≤50
>5 0
8
30
8(100.0)
16(53.3)
Tumor site 0.393
colon
rectum
21
17
12(57.1)
12(70.6)
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cerous tissues, heterogeneous staining manifested com-
monly. The cancerous cells were positively or strongly
stained in some areas while negatively or weakly stained
in other areas of the same tissue. It suggests that several
asynchronized circadian clocks may operate in different
sub-populations within the same tumor simultaneously.
Furthermore, in cancerous tissues, well-differentiated
cells seem to have higher level of hPer2 compared to
that in the poorly-differentiated cells. This phenomenon
may suggest that inactivation of hPer2 not only corre-
lates with colorectal tumor initiation but also plays a
role in tumor progression.
We further analyzed hPer2 expression patterns with
clinical-pathological features of these colorectal tumor
tissues. We found that cancerous tissues with high
grades of histopathological changes and advanced stages
of TNM classification showed statistically weaker hPer2
protein expression, especially in those patients under 50.
Since these clinical-pathological features correlate with
relatively poor prognosis of colorectal cancer patients,
low hPer2 expression may be utilized as one of the
prognostic biomarkers for colorectal cancer and worth
further investigation in a larger sample set. In our study,
a relation of low expression of hPer2 in tumor tissues
with strong Ki67 was also found. It suggests that
deregulated expression of hPer2 may contribute to the
highly proliferative property of colorectal cancer cells.
Previous studies have shown that aberrant expression of
circadian clock genes could have important conse-
quences on the transactivation of downstream targets
that control the cell cycle and on the ability of cells to
undergo apoptosis, potentially promoting carcinogenesis
[1,2]. C-erB-2 and p53 were shown to be partly con-
t r o l l e db yh P e r 2i nt h ec o u r s eo ft u m o rp r o g r e s s i o n
[6,10]. However, in this study, we observed no statisti-
cally significant association between low levels of hPer2
expression and positive p53 or C-erB-2, which need to
be further investigated in a larger sample set.
Recently, more direct evidences demonstrate the link
between the loss of circadian genes function and cancer
progression, but the underlying mechanisms were poorly
understood. Chen ST. et al. reported that 95% of breast
tumors (56 out of 59 specimens) displays no or deregu-
lated level of Per1, Per2 or Per3 proteins in the breast
tumor cells when compared the adjacent normal tissues
[6]. Yeh et al. found that the expression level of Per1
was significantly decreased in endometrial carcinoma
Table 3 Relationship between expression levels of hPer2 protein in colorectal carcinoma and pathological features
clinical-pathological features Decreased hPer2 expression in tumor
n
Non-Decreased hPer2 expression in tumor
n
P
Pathology Type 0.235
protrude
infiltrating
ulcer
7
3
14
8
1
5
Histological Grade 0.017
I, II
III
16
8
14
0
Depth of Tumor Invasion 0.044
Tis~T2
T3~T4
3
21
6
8
Lymph Nodes Spread 0.043
negative
positive
10
14
11
3
TNM Stage 0.021
I
II
III+IV
2
8
14
6
5
3
p53 0.167
(-)
(+)
2
22
4
10
C-erB-2 0.804
(-)
(+)
13
11
7
7
Table 4 Relationship between the reduced expression of
hPer2 protein and Ki67 in colorectal cancer patients
low hPer2 expression in tumor Ki67
n ¯ x ±s P
Negative 14 0.476 ± 0.262 0.046
Positive 24 0.638 ± 0.214
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was due to DNA methylation of the promoters rather
than gene mutations of the clock genes. Later, Remco et
al. identified the miR-192 ⁄ 194 cluster as a potent inhi-
bitor of the entire Period gene family using a forward
genetic screen, unveiling a new mechanism for the
downregulation of the circadian clock genes at the post-
transcriptional level [35]. To elucidate a possible
mechanism to explain the hPer2 expression patterns in
colorectal cancer, we further analyzed hPer2 mRNA
levels in these 24 paired tissues which showed low
expression of Per2 protein in tumor. Our results showed
that the mRNA levels of Per2 were also decreased in
cancerous tissues. It suggests that other factors rather
than miR-192⁄194 cluster may be responsible for the
hPer2 gene deregulation in CRC progression. Since it
has been shown that CpG methylation can inactivate
promoter function, leading to inhibition of hPer gene
promoter function in breast and endometrial carcinoma,
whether CpG methylation on the PER2 promoter contri-
butes to human colorectal cancer development needs
further investigation.
Both genetic and molecular studies have shown that
hPer2 is a tumor suppressor that controls cell prolifera-
tion and promotes apoptosis. Our data suggest that
aberrant expression of the hPer2 gene may be associated
with the development of carcinomas in the colorectal tis-
sues and may provide a molecular basis for the clinical
application of chronotherapy in CRC treatment. How-
ever, the mechanisms leading to the reduced expression
of hPer2 and the manner in which hPer2 suppresses
tumorigenesis remains unclear. Further studies are still
necessary to elucidate the role of hPer2 in CRC.
Conclusions
Our study showed hPer2 expression decreased in human
CRC tissues, and well-differentiated cancer cells are
more likely to maintain hPer2 expression than poorly-
differentiated ones. Furthermore, associations of
decreased hPer2 levels with patients’ age, histological
grade, TNM stage and expression of nucleus prolifera-
tion related antigen: Ki67 were also detected. These
results suggest a role for hPer2 in normal colorectal cell
function and the potential deregulation of hPer2 expres-
sion in the development, invasion, and metastasis of
CRC.
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